PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with 20 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
High success rate customer satisfaction in 2022: 97.5%
When is your turn?
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex to present the effects of semaglutide in aged pre-cirrhotic hamsters at the 10th Aging Research and Drug Discovery Meeting
Physiogenex will be presenting a new NASH hamster study at the 10th Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen, Denmark, August...
Physiogenex to present a new diabetic NASH HFpEF hamster study at the 83rd American Diabetes Association meeting in San Diego, CA, USA, June 23-26, 2023
Physiogenex will be presenting a new DIABETIC NASH HFpEF hamster study at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, CA,...
Physiogenex to present at the 1st T2D & Obesity Therapeutics Summit in Boston, MA, May 31 – June 1st, 2023
Physiogenex is a proud sponsor of the Hanson Wade 1st Type 2 diabetes & Obesity Therapeutics Summit to be held in Boston, May 30th - June 1st, 2023: On...